Janssen-Cilag GmbH

General information

Janssen-Cilag GmbH
Johnson & Johnson Platz 1
41470 Neuss, North Rhine-Westphalia
Germany

Contact person: Peter Solberg, Managing Director
Company main phone: +49 (2137) 9550
Company main fax: +49 (2137) 955327
Website: www.janssen-cilag.de

Year founded:	1959
Source of foundation:	Subsidiary
Name of foundation source:	Johnson & Johnson
No. of employees:	Worldwide: 40000

Corporate description / mission:
Janssen-Cilag GmbH manufactures and markets pharmaceutical products. The company is dedicated to addressing and solving the most important unmet medical needs including oncology (multiple myeloma and prostate cancer), immunology (psoriasis), neuroscience (schizophrenia, dementia, pain), infectious diseases (HIV/AIDS, hepatitis C, tuberculosis), and cardiovascular and metabolic diseases (diabetes).

State of ownership: Subsidiary
Headquarters: No

Remarks on ownership / listings
Janssen-Cilag, a subsidiary of the healthcare group Johnson & Johnson is an international research-based pharmaceutical company.

Categorization

Sector:

Pharma (fully integrated)

Subsector:

Anti-infectives
Vaccines
Other

Primary therapeutic areas:

Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the nervous system / neurology
Infectious and parasitic diseases / infectiology / parasitology
Mental and behavioural disorders / psychiatry /psychology
Neoplasms / cancer / oncology
Skin and subcutaneous tissue / dermatology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

Manufacturer
R&D
Subsidiary
Supplier / Distributor

Customer segments:

Consumers (mass market)
Hospitals
Physicians / doctors

Distribution:

Direct (own sales force)
Indirect (independent dealer)

Summary Products / Services / Technologies

Description of products:
Caelyx®
Erypo FS®
Imbruvica®
Prezista®
Stelara®, etc.